Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.74 SEK | +9.25% | +27.78% | +20.05% |
25/03 | Senzagen Receives Follow-Up Order Worth SEK 0.8 Million from the Global Chemicals Leader | CI |
22/03 | SenzaGen AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+20.05% | 17.91M | - | ||
-14.37% | 11.41B | A- | ||
+70.73% | 3.81B | D+ | ||
-29.39% | 2.3B | C | ||
-12.90% | 2.16B | - | B- | |
+37.56% | 1.19B | B- | ||
-2.40% | 760M | C+ | ||
-15.17% | 506M | C- | ||
-34.29% | 444M | C- | ||
+13.72% | 339M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- SENZA Stock
- Ratings SenzaGen AB